<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211215053419N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-02-26</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Efficacy of ultrasound guided pectoral nerve block versus serratus anterior block on pain</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of efficacy of ultrasound guided pectoral nerve block (PECS II) versus serratus anterior block (SAB) on postoperative pain in breast cancer surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-03-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/60902</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Other, Randomization description: Patients will be randomly assigned to two groups by using a random number table. In order to randomize, a random block method will be used. For this purpose, we formed blocks of size 4. In each block, 2 individuals will be in intervention group 1 and 2 will be in intervention group 2. A total of 20 blocks will be considered for the study.
Random Block Quadruple All possible blocks are arranged as follows: block 1: ABAB block 2: AABB block 3: ABBA block 4: BBAA block 5: BABA block 6: BAAB We need 20 blocks to select 80 people. We randomly select these blocks from 1 to 6. Using the software, we choose a random number between the numbers 1 to 6. For example, if the number 6 is selected as the first block and the number 2 as the second block, the people who enter the study will be given BAABAABB, respectively. Finally, group A receives control intervention and group B receives treatment intervention, Blinding description: Patients will be unaware and blind to the type of treatment. Similar envelopes were used for hiding, without the name tag of the block method and only with the code. Patients will be aware that they will be randomly assigned to one of two treatment groups, but will not know which treatment will be offered in that group. Patients will be placed in one of two groups using a table of random numbers. The data collector and analyst will collect and analyze the information based on groups 1 and 2, and will not be aware of the type of treatment provided in the groups and will be kept blind.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Breast cancer.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Type II pectoral nerve block. The block will be performed after general anesthesia. The purpose of this block is to penetrate the two fascia compartments by dividing the dose of local anesthesia between the pectoral nerve in the pectoralis minor muscle. This block is performed by placing the patient supine and placing the surgical side arm in a 90 degree position. The linear transducer is located on the outer side of the midline of the clavicle at the level of the third rib, and in the first injection approximately 0.2 ml per kg of ropivacine is injected 0.25 between the pectoralis major and minor muscles, for lateral and medial pectoral nerve blocks. The transducer is rotated slightly to create a path for the needle from the top and inside to the side. While the second injection was in the axillary anterior line and at the level of the fourth gear with 0.2 ml per kg of ropivacine 0.25 between the pectoralis minor and the anterior ceratus muscle, using a linear transducer with a depth of 1 to 4 cm and a needle. Local block is performed. The injection depth is usually 1 to 3 cm for the first injection and 3 to 6 cm for the second injection. Intervention 2: Intervention group 2:Anterior Ceratus block under ultrasound guide. The block will be performed after general anesthesia under an ultrasound guide with a portable ultrasound device. In this block the linear transducer is located on the midaxillary line and at the level of the fifth gear. A block needle is inserted from the outer edge of the transducer and moves forward until the tip of the needle reaches each plate between the thoracic fascia on the ultrasound image. Following the detection of ultrasound signs, a linear transducer with a depth of 1 to 4 cm and a local block needle can be performed and an injection of 0.4 ml per kg of ropivacaine 0.25 block will be performed.                                                        Device model: Portable Sono Site, HFL50X/15-6 MHz Trancducer، Made in USA.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Parinaz Morovati Sharif Abadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hazrate Rasool hospital, Niyayesh street, Sattarkhan</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>+98 21 4608 8077</telephone>
        <email>parinazmorovati43589@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Parinaz Morovati Sharif Abadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hazrate Rasool hospital, Niyayesh street, Sattarkhan</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>+98 21 4608 8077</telephone>
        <email>parinazmorovati43589@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients over 18 years old
Candidate for lumpectomy or partial mastectomy
Perform surgery under general anesthesia</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Prohibition of any nerve block
History of bleeding disease
Drug allergy
History of liver or kidney failure
Obesity
Pregnancy or lactation
History of drugs addiction
History of neurological diseases
Infection of the site of the block
History of breast surgery
Patients over 60 years old</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>C50</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Malignant neoplasm of breast</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Type II pectoral nerve block. The block will be performed after general anesthesia. The purpose of this block is to penetrate the two fascia compartments by dividing the dose of local anesthesia between the pectoral nerve in the pectoralis minor muscle. This block is performed by placing the patient supine and placing the surgical side arm in a 90 degree position. The linear transducer is located on the outer side of the midline of the clavicle at the level of the third rib, and in the first injection approximately 0.2 ml per kg of ropivacine is injected 0.25 between the pectoralis major and minor muscles, for lateral and medial pectoral nerve blocks. The transducer is rotated slightly to create a path for the needle from the top and inside to the side. While the second injection was in the axillary anterior line and at the level of the fourth gear with 0.2 ml per kg of ropivacine 0.25 between the pectoralis minor and the anterior ceratus muscle, using a linear transducer with a depth of 1 to 4 cm and a needle. Local block is performed. The injection depth is usually 1 to 3 cm for the first injection and 3 to 6 cm for the second injection.</i_keyword>
      <i_keyword>Intervention group 2:Anterior Ceratus block under ultrasound guide. The block will be performed after general anesthesia under an ultrasound guide with a portable ultrasound device. In this block the linear transducer is located on the midaxillary line and at the level of the fifth gear. A block needle is inserted from the outer edge of the transducer and moves forward until the tip of the needle reaches each plate between the thoracic fascia on the ultrasound image. Following the detection of ultrasound signs, a linear transducer with a depth of 1 to 4 cm and a local block needle can be performed and an injection of 0.4 ml per kg of ropivacaine 0.25 block will be performed.                                                        Device model: Portable Sono Site, HFL50X/15-6 MHz Trancducer، Made in USA.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The amount of pain. Timepoint: 6, 12 and 24 hours after surgery. Method of measurement: Based on Numerical Rating Scale.</prim_outcome>
      <prim_outcome>Patient satisfaction. Timepoint: 6, 12 and 24 hours after surgery. Method of measurement: Based on Likert scale.</prim_outcome>
      <prim_outcome>Patient analgesia. Timepoint: 6, 12 and 24 hours after surgery. Method of measurement: Ramsay sedation scale.</prim_outcome>
      <prim_outcome>Total dose of anesthesia. Timepoint: After surgery. Method of measurement: Based on patient records.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-12-04</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences, Hemmat Highway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
